A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants

NCT06281158 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: [14C]-DNL343

Sponsor

Denali Therapeutics Inc.